EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END
/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...
USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the...
/PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in...
FN Media Group Presents USA News Group News Commentary  Vancouver, BC – September 26, 2023 – USA News Group  – The seriousness of pancreatic cancer continues to grow, with increasing alarm since...
USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in April 2023, showing a rising incidence of pancreatic cancer...
The consensus price target hints at an 114.6% upside potential for Merus N.V. (MRUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...
Merus N.V. (MRUS) delivered earnings and revenue surprises of 19.63% and 27.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -8.16% and 36.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.